Рекомбинантный рецепторный антагонист интерлейкина-1 человека
Рекомбинантный рецепторный антагонист интерлейкина-1 человека Uses, Dosage, Side Effects, Food Interaction and all others data.
Рекомбинантный рецепторный антагонист интерлейкина-1 человека is a recombinant, nonglycosylated human interleukin-1 receptor antagonist (IL-1Ra). The difference between anakinra and the native human IL-1Ra is that anakinra has an extra methionine residue at the amino terminus. It is manufactured by using the E. coli expression system. Рекомбинантный рецепторный антагонист интерлейкина-1 человека is composed of 153 amino acid residues. FDA approved on November 14, 2001.
Used to treat rheumatoid arthritis, Рекомбинантный рецепторный антагонист интерлейкина-1 человека blocks the biologic activity of IL-1 by competitively inhibiting IL-1 binding to the interleukin-1 type I receptor (IL-1RI), which is expressed in a wide variety of tissues and organs. IL-1 production is induced in response to inflammatory stimuli and mediates various physiologic responses including inflammatory and immunological responses. Patients with rheumatoid arthritis have elevated levels of IL-1. The levels of the naturally occurring IL-1Ra in synovium and synovial fluid from rheumatoid arthritis (RA) patients are not sufficient to compete with the elevated amount of locally produced IL-1. Increasing the levels of IL-1Ra by artificial means reduces the negative effects (cartilage degradation, bone resorption) of IL-1.
Table Of contents
Trade Name | Рекомбинантный рецепторный антагонист интерлейкина-1 человека |
Availability | Prescription only |
Generic | Anakinra |
Anakinra Other Names | Anakinra, IL-1RA, Interleukin-1 receptor antagonist anakinra |
Related Drugs | Actemra, Kineret, Ilaris, Humira, hydroxychloroquine, Enbrel, Remicade, Rituxan, Orencia, Arcalyst |
Type | |
Formula | C759H1186N208O232S10 |
Weight | 17257.6 Da |
Groups | Approved |
Therapeutic Class | |
Manufacturer | |
Available Country | Russia |
Last Updated: | September 19, 2023 at 7:00 am |
![Рекомбинантный рецепторный антагонист интерлейкина-1 человека Рекомбинантный рецепторный антагонист интерлейкина-1 человека](https://www.medicinesfaq.com/media/png/rekombinantnyy-receptornyy-antagonist-interleykina-1-cheloveka.png)
Uses
Рекомбинантный рецепторный антагонист интерлейкина-1 человека is a recombinant form of human interleukin-1 receptor antagonist used in the treatment of rheumatoid arthritis and neonatal-onset multisystem inflammatory disease.
For the treatment of adult rheumatoid arthritis and treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID).
Рекомбинантный рецепторный антагонист интерлейкина-1 человека is also used to associated treatment for these conditions: Juvenile Idiopathic Arthritis (JIA), Neonatal-Onset Multisystem Inflammatory Disease (NOMID), Moderate Rheumatoid arthritis, Recurrent Pericarditis, Severe Rheumatoid arthritis
How Рекомбинантный рецепторный антагонист интерлейкина-1 человека works
Рекомбинантный рецепторный антагонист интерлейкина-1 человека binds competitively to the Interleukin-1 type I receptor (IL-1RI), thereby inhibiting the action of elevated levels IL-1 which normally can lead to cartilage degradation and bone resorption.
Toxicity
Most common adverse reactions (incidence ≥ 5%) are injection site reaction, worsening of rheumatoid arthritis, upper respiratory tract infection, headache, nausea, diarrhea, sinusitis, arthralgia, flu like-symptoms, and abdominal pain when anakinra is used in RA patients. In NOMID patients, the most common AEs during the first 6 months of treatment (incidence >10%) are injection site reaction, headache, vomiting, arthralgia, pyrexia, and nasopharyngitis.
Food Interaction
No interactions found.Рекомбинантный рецепторный антагонист интерлейкина-1 человека Drug Interaction
Unknown: charcoal, charcoal, amoxicillin / clavulanate, amoxicillin / clavulanate, duloxetine, duloxetine, sodium iodide, sodium iodide, acetaminophen, acetaminophen, bioflavonoids, bioflavonoids, cyanocobalamin, cyanocobalamin, pyridoxine, pyridoxine, ascorbic acid, ascorbic acid, cholecalciferol, cholecalciferol
Рекомбинантный рецепторный антагонист интерлейкина-1 человека Disease Interaction
Major: infections, renal deficiency, tuberculosisModerate: liver disease, neutropenia
Elimination Route
When a 70 mg subcutaneous bolus injection is given to healthy subjects, the absolute bioavailability is 95%. Accumulation does not occur following daily subcutaneous doses. Tmax, SubQ, 1-2 mg/kg, healthy subjects = 3-7 hours; Cmax, SubQ, 3 mg/kg once daily, NOMID patients = 3628 ng/mL.
Half Life
Healthy subjects = 4 - 6 hours; NOMID patients = 5.7 hours (range of 3.1 - 28.2 hours).
Clearance
Clearance is variable and increases with increasing creatinine clearance and body weight. However, gender and age were not significant factors.
Innovators Monograph
You find simplified version here Рекомбинантный рецепторный антагонист интерлейкина-1 человека